Cerenome

CNSY

시가총액 US$1290만

CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.

Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026: CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA) CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA) CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions.

Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript

Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.

HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc.  (Nasdaq:  CNSY ) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m.

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc.  (Nasdaq:  CNSY ) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems.

Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments.

Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.